Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of neoadjuvant TP versus TAC in operable triple-negative breast cancer
ChiCTR1800019501Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, cisplatin, doxorubicin and cyclophosphamide in breast cancer and triple-negative breast cancer (TNBC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological complete response rate. Started Nov 2018; status: completed.
02
Drugs
docetaxelcisplatindoxorubicincyclophosphamide
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR1800019501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019501.